Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Epidural Spinal Cord Stimulation Improves Motor Function in Rats With Chemically Induced Parkinsonism.

Zhong H, Zhu C, Minegishi Y, Richter F, Zdunowski S, Roy RR, Vissel B, Gad P, Gerasimenko Y, Chesselet MF, Edgerton VR.

Neurorehabil Neural Repair. 2019 Nov 5:1545968319876891. doi: 10.1177/1545968319876891. [Epub ahead of print]

PMID:
31684831
2.

TEMPORARY REMOVAL: Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.

Rentsch P, Stayte S, Egan T, Clark I, Vissel B.

Neurobiol Dis. 2019 Oct 25:104646. doi: 10.1016/j.nbd.2019.104646. [Epub ahead of print] No abstract available.

3.

The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain.

Stayte S, Laloli KJ, Rentsch P, Lowth A, Li KM, Pickford R, Vissel B.

Exp Neurol. 2019 Sep 9;323:113062. doi: 10.1016/j.expneurol.2019.113062. [Epub ahead of print]

PMID:
31513786
4.

Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary.

Clark IA, Vissel B.

Expert Rev Neurother. 2019 Jun;19(6):535-543. doi: 10.1080/14737175.2019.1618710. Epub 2019 May 24.

PMID:
31092047
5.
6.

Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease.

Morris GP, Clark IA, Vissel B.

Acta Neuropathol. 2018 Nov;136(5):663-689. doi: 10.1007/s00401-018-1918-8. Epub 2018 Oct 22. Review.

7.

Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases.

Clark IA, Vissel B.

Br J Pharmacol. 2018 Oct;175(20):3859-3875. doi: 10.1111/bph.14471. Epub 2018 Sep 6. Review.

8.

L-Carnitine and extendin-4 improve outcomes following moderate brain contusion injury.

Chen H, Chan YL, Linnane C, Mao Y, Anwer AG, Sapkota A, Annissa TF, Herok G, Vissel B, Oliver BG, Saad S, Gorrie CA.

Sci Rep. 2018 Jul 25;8(1):11201. doi: 10.1038/s41598-018-29430-6.

9.

The Inflammatory Nature of Post-surgical Delirium Predicts Benefit of Agents With Anti-TNF Effects, Such as Dexmedetomidine.

Clark IA, Vissel B.

Front Neurosci. 2018 Apr 19;12:257. doi: 10.3389/fnins.2018.00257. eCollection 2018. No abstract available.

10.

Adar3 Is Involved in Learning and Memory in Mice.

Mladenova D, Barry G, Konen LM, Pineda SS, Guennewig B, Avesson L, Zinn R, Schonrock N, Bitar M, Jonkhout N, Crumlish L, Kaczorowski DC, Gong A, Pinese M, Franco GR, Walkley CR, Vissel B, Mattick JS.

Front Neurosci. 2018 Apr 13;12:243. doi: 10.3389/fnins.2018.00243. eCollection 2018.

11.

High dietary fat and sucrose results in an extensive and time-dependent deterioration in health of multiple physiological systems in mice.

Burchfield JG, Kebede MA, Meoli CC, Stöckli J, Whitworth PT, Wright AL, Hoffman NJ, Minard AY, Ma X, Krycer JR, Nelson ME, Tan SX, Yau B, Thomas KC, Wee NKY, Khor EC, Enriquez RF, Vissel B, Biden TJ, Baldock PA, Hoehn KL, Cantley J, Cooney GJ, James DE, Fazakerley DJ.

J Biol Chem. 2018 Apr 13;293(15):5731-5745. doi: 10.1074/jbc.RA117.000808. Epub 2018 Feb 13.

12.

New hope for devastating neurodegenerative disease.

Stayte S, Vissel B.

Brain. 2017 May 1;140(5):1177-1179. doi: 10.1093/brain/awx064. No abstract available.

13.

Maternal Cigarette Smoke Exposure Worsens Neurological Outcomes in Adolescent Offspring with Hypoxic-Ischemic Injury.

Chan YL, Saad S, Machaalani R, Oliver BG, Vissel B, Pollock C, Jones NM, Chen H.

Front Mol Neurosci. 2017 Sep 26;10:306. doi: 10.3389/fnmol.2017.00306. eCollection 2017. Erratum in: Front Mol Neurosci. 2018 Mar 12;11:84.

14.

The meteorology of cytokine storms, and the clinical usefulness of this knowledge.

Clark IA, Vissel B.

Semin Immunopathol. 2017 Jul;39(5):505-516. doi: 10.1007/s00281-017-0628-y. Epub 2017 Apr 27. Review.

15.

Dissociation between complete hippocampal context memory formation and context fear acquisition.

Leake J, Zinn R, Corbit L, Vissel B.

Learn Mem. 2017 Mar 15;24(4):153-157. doi: 10.1101/lm.044578.116. Print 2017 Apr.

16.

Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.

Stayte S, Rentsch P, Tröscher AR, Bamberger M, Li KM, Vissel B.

PLoS One. 2017 Jan 25;12(1):e0167211. doi: 10.1371/journal.pone.0167211. eCollection 2017.

17.
18.

CAST your vote: is calpain inhibition the answer to ALS?

Wright AL, Vissel B.

J Neurochem. 2016 Apr;137(2):140-1. doi: 10.1111/jnc.13296. Epub 2016 Mar 23.

19.

A Comparative Study of Variables Influencing Ischemic Injury in the Longa and Koizumi Methods of Intraluminal Filament Middle Cerebral Artery Occlusion in Mice.

Morris GP, Wright AL, Tan RP, Gladbach A, Ittner LM, Vissel B.

PLoS One. 2016 Feb 12;11(2):e0148503. doi: 10.1371/journal.pone.0148503. eCollection 2016.

20.

A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease.

Clark IA, Vissel B.

Neural Plast. 2015;2015:358263. doi: 10.1155/2015/358263. Epub 2015 Jul 22. Review.

21.

Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease.

Clark IA, Vissel B.

Br J Pharmacol. 2015 Aug;172(15):3714-27. doi: 10.1111/bph.13181. Epub 2015 Jun 29. Review.

22.

Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.

Stayte S, Rentsch P, Li KM, Vissel B.

PLoS One. 2015 Apr 22;10(4):e0124325. doi: 10.1371/journal.pone.0124325. eCollection 2015.

23.

Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.

Morris GP, Clark IA, Vissel B.

Acta Neuropathol Commun. 2014 Sep 18;2:135. doi: 10.1186/s40478-014-0135-5. Review.

24.

Advances in non-dopaminergic treatments for Parkinson's disease.

Stayte S, Vissel B.

Front Neurosci. 2014 May 22;8:113. doi: 10.3389/fnins.2014.00113. eCollection 2014. Review.

25.

Inflammation-sleep interface in brain disease: TNF, insulin, orexin.

Clark IA, Vissel B.

J Neuroinflammation. 2014 Mar 21;11:51. doi: 10.1186/1742-2094-11-51. Review.

26.

Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease.

Clark IA, Vissel B.

Biochem Pharmacol. 2013 Oct 1;86(7):862-71. doi: 10.1016/j.bcp.2013.07.030. Epub 2013 Aug 9. Review.

PMID:
23939185
27.

Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research.

Morris GP, Clark IA, Zinn R, Vissel B.

Neurobiol Learn Mem. 2013 Oct;105:40-53. doi: 10.1016/j.nlm.2013.07.002. Epub 2013 Jul 10. Review.

PMID:
23850597
28.

Prefrontal microcircuit underlies contextual learning after hippocampal loss.

Zelikowsky M, Bissiere S, Hast TA, Bennett RZ, Abdipranoto A, Vissel B, Fanselow MS.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9938-43. doi: 10.1073/pnas.1301691110. Epub 2013 May 15.

29.

Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease.

Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B.

PLoS One. 2013;8(4):e59586. doi: 10.1371/journal.pone.0059586. Epub 2013 Apr 1.

30.

Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales.

Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B.

Pharmacol Rev. 2012 Oct;64(4):1004-26. doi: 10.1124/pr.112.005850. Epub 2012 Sep 10. Review.

PMID:
22966039
31.

The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain.

Wright A, Vissel B.

Front Mol Neurosci. 2012 Apr 11;5:34. doi: 10.3389/fnmol.2012.00034. eCollection 2012.

32.

TNF and leptin tell essentially the same story in Alzheimer's disease.

Clark IA, Alleva LM, Vissel B.

J Alzheimers Dis. 2011;26(2):201-5. doi: 10.3233/JAD-2011-110266.

PMID:
21593567
33.

Selective knockdown of NMDA receptors in primary afferent neurons decreases pain during phase 2 of the formalin test.

McRoberts JA, Ennes HS, Marvizón JC, Fanselow MS, Mayer EA, Vissel B.

Neuroscience. 2011 Jan 13;172:474-82. doi: 10.1016/j.neuroscience.2010.10.045. Epub 2010 Oct 23.

34.

A role for calcium-permeable AMPA receptors in synaptic plasticity and learning.

Wiltgen BJ, Royle GA, Gray EE, Abdipranoto A, Thangthaeng N, Jacobs N, Saab F, Tonegawa S, Heinemann SF, O'Dell TJ, Fanselow MS, Vissel B.

PLoS One. 2010 Sep 29;5(9). pii: e12818. doi: 10.1371/journal.pone.0012818.

35.

The roles of TNF in brain dysfunction and disease.

Clark IA, Alleva LM, Vissel B.

Pharmacol Ther. 2010 Dec;128(3):519-48. doi: 10.1016/j.pharmthera.2010.08.007. Epub 2010 Sep 8. Review.

PMID:
20813131
36.

A study of clustered data and approaches to its analysis.

Galbraith S, Daniel JA, Vissel B.

J Neurosci. 2010 Aug 11;30(32):10601-8. doi: 10.1523/JNEUROSCI.0362-10.2010.

37.

Functional heterogeneity at dopamine release sites.

Daniel JA, Galbraith S, Iacovitti L, Abdipranoto A, Vissel B.

J Neurosci. 2009 Nov 18;29(46):14670-80. doi: 10.1523/JNEUROSCI.1349-09.2009.

38.

Alzheimer's disease selective vulnerability and modeling in transgenic mice.

Götz J, Schonrock N, Vissel B, Ittner LM.

J Alzheimers Dis. 2009;18(2):243-51. doi: 10.3233/JAD-2009-1143. Review.

PMID:
19584440
39.

Activin A is essential for neurogenesis following neurodegeneration.

Abdipranoto-Cowley A, Park JS, Croucher D, Daniel J, Henshall S, Galbraith S, Mervin K, Vissel B.

Stem Cells. 2009 Jun;27(6):1330-46. doi: 10.1002/stem.80.

40.

The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.

Abdipranoto A, Wu S, Stayte S, Vissel B.

CNS Neurol Disord Drug Targets. 2008 Apr;7(2):187-210. Review.

PMID:
18537646
41.

Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.

Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B, Ravasi T, Wells CA, Hume DA, Reddel RR, Clark SJ.

Cancer Res. 2007 Dec 15;67(24):11517-27.

42.

Enhanced LTP of primary afferent neurotransmission in AMPA receptor GluR2-deficient mice.

Youn DH, Royle G, Kolaj M, Vissel B, Randić M.

Pain. 2008 May;136(1-2):158-67. Epub 2007 Sep 10.

PMID:
17826911
43.

Long-term potentiation in the hippocampal CA1 region does not require insertion and activation of GluR2-lacking AMPA receptors.

Gray EE, Fink AE, Sariñana J, Vissel B, O'Dell TJ.

J Neurophysiol. 2007 Oct;98(4):2488-92. Epub 2007 Jul 25.

44.

Production of conditional point mutant knockin mice.

Skvorak K, Vissel B, Homanics GE.

Genesis. 2006 Jul;44(7):345-53.

PMID:
16832820
45.

Probing N-methyl-D-aspartate receptor desensitization with the substituted-cysteine accessibility method.

Thomas CG, Krupp JJ, Bagley EE, Bauzon R, Heinemann SF, Vissel B, Westbrook GL.

Mol Pharmacol. 2006 Apr;69(4):1296-303. Epub 2005 Dec 23.

PMID:
16377766
46.

The effect of three inhaled anesthetics in mice harboring mutations in the GluR6 (kainate) receptor gene.

Sonner JM, Vissel B, Royle G, Maurer A, Gong D, Baron NV, Harrison N, Fanselow M, Eger EI 2nd.

Anesth Analg. 2005 Jul;101(1):143-8, table of contents.

PMID:
15976221
47.

Pathobiology of dynorphins in trauma and disease.

Hauser KF, Aldrich JV, Anderson KJ, Bakalkin G, Christie MJ, Hall ED, Knapp PE, Scheff SW, Singh IN, Vissel B, Woods AS, Yakovleva T, Shippenberg TS.

Front Biosci. 2005 Jan 1;10:216-35. Print 2005 Jan 1. Review.

48.

Loss of GLUR2 alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor subunit differentially affects remaining synaptic glutamate receptors in cerebellum and cochlear nuclei.

Petralia RS, Sans N, Wang YX, Vissel B, Chang K, Noben-Trauth K, Heinemann SF, Wenthold RJ.

Eur J Neurosci. 2004 Apr;19(8):2017-29.

PMID:
15090029
49.

Aberrant formation of glutamate receptor complexes in hippocampal neurons of mice lacking the GluR2 AMPA receptor subunit.

Sans N, Vissel B, Petralia RS, Wang YX, Chang K, Royle GA, Wang CY, O'Gorman S, Heinemann SF, Wenthold RJ.

J Neurosci. 2003 Oct 15;23(28):9367-73.

50.

Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration.

Sonner JM, Antognini JF, Dutton RC, Flood P, Gray AT, Harris RA, Homanics GE, Kendig J, Orser B, Raines DE, Rampil IJ, Trudell J, Vissel B, Eger EI 2nd.

Anesth Analg. 2003 Sep;97(3):718-40. Review. Erratum in: Anesth Analg. 2004 Jan;98(1):29.

PMID:
12933393

Supplemental Content

Loading ...
Support Center